Skip to main content

Table 2 Genotype and Allele Distribution of ERCC1 Polymorphisms in ovarian cancer Resistant and Responders

From: Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

SNP

Study

Resistant

Responder

Resistant

Responder

HWE

  

C/C

C/T

T/T

C

T

C/C

C/T

T/T

C

T

Number (%)

Number (%)

Chi

p

ERCC1 C19007T

Sokbom K. et al. [18]

15

5

0

35

5

20

16

4

56

24

20 (50)

40 (50)

0.09

0.76

Steffensen K.D. et al. [20]

16

72

67

104

206

15

71

58

101

187

155 (52)

144 (48)

0.98

0.32

Smith S. et al. [16]

11

22

15

44

52

23

60

45

106

150

48 (27)

128 (73)

0.15

0.71

Qi B. et al. [11]

38

26

9

102

44

78

67

2

223

71

73 (33)

147 (67)

8.76

0.003

Bösmüller H. et al. [19]

6

5

3

17

11

7

9

11

23

31

14 (34)

27 (66)

2.74

0.1

Steffensen K.D. et al. [17]

3

7

2

13

11

12

34

42

58

118

12 (12)

88 (88)

1.39

0.24

Moxley K.M. et al. [10]

10

13

9

33

31

14

8

10

36

28

32 (50)

32 (50)

8.04

0.005

Yang S. [21]

28

31

12

87

55

70

67

1

207

69

71 (34)

138 (66)

11.98

0.0005

  1. ERCC1 excision repair cross complementation group 1, HWE Hardy-Weinberg Equilibrium